Cancer reports最新文献

{"title":"Incidence and Clinical Outcomes of Vitamin D Status and Myeloma Bone Disease Among Patients With Newly Diagnosed Multiple Myeloma (MM) in a Tropical Country—Retrospective Cohort Study","authors":"Chi Ching Lim,&nbsp;Wai San Wilson Tam,&nbsp;Widanalage Sanjay Prasad De Mel,&nbsp;Siew Ping Lang,&nbsp;Wee Joo Chng,&nbsp;Cinnie Yentia Soekojo,&nbsp;Fang Fang Song,&nbsp;Melissa Gaik Ming Ooi","doi":"10.1002/cnr2.70431","DOIUrl":"10.1002/cnr2.70431","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>The retrospective data analysis on 80 patients from 2018 to 2022 aimed to determine the incidence and clinical outcomes of vitamin D status and myeloma bone disease among newly diagnosed multiple myeloma (MM) patients in Singapore.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Method</h3>\u0000 \u0000 <p>Patients' demographics, bone health data and bone disease management were collected. Chi-square test was conducted to compare variables between patients who survived versus those who demised. Survival differences were compared using log-rank analysis and plotted using Kaplan–Meier estimates. Multivariable survival analysis was conducted using Cox Regression.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Fifty-nine (73.8%) patients had myeloma bone disease at diagnosis, and 42 (71.2%) of these patients had skeletal-related adverse events at diagnosis. The compliance to bone health management needs to be optimized, as only 70 patients had their vitamin D level tested at diagnosis, of which 48 (68.7%) patients were vitamin D insufficient or deficient. Bone disease data did not correlate with mortality. Higher mortality was initially observed among patients with non-Chinese (<i>p</i> = 0.03), R-ISS 3 (<i>p</i> = 0.001), and renal involvement at diagnosis (<i>p</i> = 0.035). R-ISS staging remained the only statistically significant variable after adjusting for race (adjusted HR 3.99; 95% CI 1.58–10.07).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The study found no correlation between myeloma bone health data and survival outcomes in our centre.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 12","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12723718/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145809583","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk Factors for Infectious Adverse Events in Newly Diagnosed Acute Myeloid Leukemia Patients Treated With Venetoclax Combinations: A Retrospective Single-Centre Real-World Experience","authors":"Olgu Erkin Çınar,&nbsp;Azade Kanat,&nbsp;Kerim Erer,&nbsp;Rasim Şahin,&nbsp;Esma Eryılmaz Eren,&nbsp;Esra Yıldızhan","doi":"10.1002/cnr2.70432","DOIUrl":"10.1002/cnr2.70432","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Venetoclax-based (ven) combinations have become a standard of care for acute myeloid leukemia (AML) patients ineligible for intensive chemotherapy. However, the associated risk of infectious adverse events (IAEs) remains a significant clinical concern.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>This study aimed to evaluate the incidence, characteristics, and risk factors for IAEs in newly diagnosed AML patients treated with venetoclax combinations in a real-world setting.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods and Results</h3>\u0000 \u0000 <p>We conducted a retrospective cohort study of AML patients treated with ven in combination with hypomethylating agents or low-dose cytarabine (LDAC), with analyses performed on a treatment cycle basis. Clinical and laboratory data, including IAE characteristics, duration of neutropenia, and concomitant medications, were collected, and grade ≥ 2 IAEs were included according to CTCAE v5.0 criteria. The cohort included 143 treatment cycles of 43 patients, with a median neutropenia duration of 13 days (5–35). A total of 34 (23.8%) grade ≥ 2 IAEs occurred, with an incidence of 1 per 121 patient-days. Multivariate analysis identified prolonged neutropenia (days, OR = 1.037, <i>p</i> = 0.005) and interacting concomitant medications (OR = 9.99, <i>p</i> &lt; 0.001) as independent risk factors for IAEs. The rate of invasive fungal infections was as low as 3.5%, and the use of antifungal or antibacterial prophylaxis was not associated with a reduction in the rate of IAEs.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>IAEs remain a substantial risk in venetoclax-treated AML patients, particularly during prolonged neutropenia and with concomitant drug interactions. Optimizing venetoclax regimens and careful management of interacting medications may mitigate these risks.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 12","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12723065/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145809577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Successful Combination Therapy With Lenvatinib Plus Pembrolizumab for Rare Case of Advanced Renal Cell Carcinoma With Ocular Adnexal Metastasis","authors":"Yozo Mitsui,&nbsp;Masato Uetani,&nbsp;Fumito Yamabe,&nbsp;Hideyuki Kobayashi,&nbsp;Aki Mitsuda,&nbsp;Naobumi Tochigi,&nbsp;Koichi Nakajima","doi":"10.1002/cnr2.70437","DOIUrl":"10.1002/cnr2.70437","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Ocular adnexal (OA) metastasis from renal cell carcinoma (RCC) is a very rare end-stage entity with a poor prognosis. Reported here is a case of metastatic RCC for which combination therapy with lenvatinib plus pembrolizumab was given for OA metastasis and achieved an excellent response.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Case</h3>\u0000 \u0000 <p>A 54-year-old man was referred to our hospital complaining of right eye pain, with a right intraocular tumor showing a maximum diameter of 3 cm subsequently revealed by computed tomography (CT) imaging. Additionally, masses in the right kidney, both lungs, and right iliac bone were noted, while a subsequent percutaneous renal needle biopsy indicated RCC with multiple metastases (cT3aN0M1). Administration of lenvatinib plus pembrolizumab combination therapy was given as first-line treatment, with rapid improvement of the elevated inflammatory response and anemia noted. Findings obtained 17 months following initiation of therapy showed significant shrinkage of the primary and iliac bone lesions, while the OA and lung metastatic lesions had completely disappeared.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>These results highlight the potential of lenvatinib plus pembrolizumab combination therapy for the treatment of RCC with OA metastasis, which is generally considered to be an end stage for cancer cases.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 12","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12719607/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145803200","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fuelling Neuroblastoma: Genomic Analysis of Ketolytic and Glycolytic Gene Expression in Relation to MYCN Oncogene Amplification, Stage and Prognosis","authors":"Joseph W. Molloy,&nbsp;Karl Keogh,&nbsp;Mary-Kate McLoughlin,&nbsp;Lauren Devitt,&nbsp;David Lee,&nbsp;Eric Downer,&nbsp;David Robert Grimes,&nbsp;Denis Barry","doi":"10.1002/cnr2.70429","DOIUrl":"10.1002/cnr2.70429","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Neuroblastoma (NB) is a childhood cancer of the sympathetic nervous system, and its prognosis is poor. NB cells undergo transcriptional changes to utilise aerobic glycolysis as their primary metabolic pathway, which provides an immediate source of ATP to meet high biosynthetic demands. Alternative metabolic fuel inputs, including ketone bodies which require oxidative phosphorylation, may impact the proliferative capacity of NB.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>In this exploratory study, the expression of glycolytic and ketolytic genes in the context of MYCN oncogene amplification, tumour staging 1–4 and Kaplan–Meier survivability was investigated using the R2: Genomics analysis and visualisation platform (http://r2.amc.nl), database.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods and Results</h3>\u0000 \u0000 <p>Three NB genomics datasets were assessed in the R2 platform and further analysed in GraphPad Prism to investigate the relationships between glycolytic and ketolytic gene expression and prognosis. Glycolytic gene expression is increased in MYCN amplified, metastatic tumours and is associated with worse event free survival. Ketolytic gene expression is lower in metastatic tumours and is associated with better event free survivability. The glycolytic gene expression profile of NB suggests that elevated levels correlate with a low probability of survival. Ketolytic gene expression patterns suggest a decreased reliance for ketolytic energy, which may be exploited to slow tumourigenic growth.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>This study validates glycolytic and ketolytic gene expression profiles in metastatic and MYCN amplified NB tumours and through conditional analysis suggests the potential use of these genes in prognosis prediction. Furthermore, the study highlights the reliability and utility of genomic databases as oncogenomic tools for NB research.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 12","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12717149/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145793395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing Second-Line Treatment Strategies and Outcomes in Epidermal Growth Factor Receptor (EGFR) Oncogene-Driven Stage IV Non-Small Cell Lung Cancer, Following a First-Line EGFR-TKI Therapy","authors":"Meghana Maddula,&nbsp;Annelise Decaria,&nbsp;Bea Brown,&nbsp;John Simes,&nbsp;Michael Boyer,&nbsp;Venessa Chin","doi":"10.1002/cnr2.70428","DOIUrl":"10.1002/cnr2.70428","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Background&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Oncogene-driven metastatic non-small cell lung cancer (mNSCLC) is associated with poor survival outcomes, despite advancements in first-line tyrosine kinase inhibitor (TKI) therapies.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Aims&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;This study aimed to characterise second-line treatment strategies for epidermal growth factor receptor (EGFR)-driven mNSCLC, and to evaluate associated clinical outcomes using real-world data.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Materials&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;The EnRICH study prospectively collected clinical data on patients diagnosed with lung cancer from NSW, Australia. Patients with EGFR-driven mNSCLC who received second-line therapy following progression on first-line EGFR-TKI were included in this analysis. Outcomes assessed included progression-free survival (PFS2) and overall survival (OS), measured from second-line treatment.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Of 2000 patients with newly diagnosed lung cancer, between 2016 and 2021, 1720 had NSCLC and 679 had metastatic disease. Among these, 647 underwent molecular testing, with 133 harboring an EGFR mutation. Of these 133, 80 patients received first-line TKI therapy. From this group, 68 who subsequently received second-line treatment following disease progression on first-line TKI were included in this analysis. Of these 68 patients, 77% (&lt;i&gt;n&lt;/i&gt; = 52/68) were treated with a first- or second-generation TKI (Erlotinib: &lt;i&gt;n&lt;/i&gt; = 39, Gefitinib: &lt;i&gt;n&lt;/i&gt; = 7, Afatinib: &lt;i&gt;n&lt;/i&gt; = 6) in the first-line setting. The remaining 16 patients received the third-generation TKI Osimertinib. Of the total 68 patients in this cohort, in the second-line setting, 45 patients underwent a change in their systemic therapy, and the remaining 23 patients received radiotherapy either with cessation of first-line TKI (&lt;i&gt;n&lt;/i&gt; = 11) or in addition to continuation of first-line TKI (&lt;i&gt;n&lt;/i&gt; = 12). Of the 45 patients who underwent a change in their systemic therapy, 32 received systemic therapy alone in the second-line setting and 13 received radiotherapy in addition to a change in systemic therapy. Of these 45 patients, 33 received a TKI, with the majority receiving Osimertinib (&lt;i&gt;n&lt;/i&gt; = 28). Median PFS2 was 3.0 months (95% CI: 1.32–5.49), with no significant difference between patients treated with second-line TKI and those receiving other therapies (&lt;i&gt;p&lt;/i&gt; = 0.24). Median OS was 15.0 months (95% CI: 13.24–23.66) and similarly did not differ significantly between second-line TKI and alternative treatment strategies (&lt;i&gt;p&lt;/i&gt; = 0.17).&lt;/p&gt;\u0000 ","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 12","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12710434/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145767279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Toward Precision Medicine: Gene Therapy Applications in the Management of Uveal Melanoma","authors":"Alireza Azani,&nbsp;Vahid Ghassemifar,&nbsp;Zahra Mehrdad,&nbsp;Maryam Saberivand,&nbsp;Anahid Bagheripour,&nbsp;Safa Tahmasebi,&nbsp;Hossein Gharedaghi,&nbsp;Malihe Sharafi,&nbsp;Hassan Foroozand,&nbsp;Mohammad Saeed Soleimani Meigoli,&nbsp;Saba Pourali,&nbsp;Arash Salmaninejad,&nbsp;Faeze Ahmadi Beni,&nbsp;Qumars Behfar","doi":"10.1002/cnr2.70425","DOIUrl":"10.1002/cnr2.70425","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Uveal melanoma (UM) is the prevailing malignant tumor that develops within the eye in adults, and it has a bleak outlook because of the few treatment choices available and the high likelihood of returning after treatment. Currently, surgical intervention, radiation therapy, and a combination of both modalities are available therapeutic modalities for controlling UM. However, these techniques are associated with notable adverse effects and have limited efficacy. Therefore, there is a lack of sufficient and reliable therapies for UM, especially for advanced and metastatic UM forms. This review aims to summarize the clinical features and current therapies of UM and highlight recent progress in gene therapy approaches.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Recent Findings</h3>\u0000 \u0000 <p>Significant developments in gene therapy have introduced multiple strategies for targeting UM. Gene silencing using siRNA and shRNA has shown efficacy in downregulating oncogenic pathways. CRISPR/Cas9-based editing has enabled selective disruption of tumor-promoting genes, sensitizing tumor cells to targeted inhibitors. Restoration of tumor-suppressive miRNAs has reduced proliferation, migration, and invasion of UM cells in preclinical models. Suicide gene therapy has demonstrated potent cytotoxicity in xenografts. Moreover, oncolytic viruses and stem-cell–associated delivery systems provide novel mechanisms for tumor-selective gene expression and immune activation. Although challenges persist—such as delivery efficiency, immune responses, and genetic heterogeneity—ongoing innovations in vector design, non-viral nanoformulations, and mutation-guided therapies continue to enhance clinical feasibility.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Gene therapy provides improved safety profiles and the possibility of tailored treatment strategies by integrating information on gene expression patterns and DNA alterations. In the future, gene therapy has the potential to improve the treatment of UM by targeting specific genetic mutations driving tumor growth and may offer new hope for patients with advanced stages of UM.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 12","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12703015/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145755386","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploitation of Biocomputational Approaches for siRNA-Mediated Gene Silencing of HPV: A Novel Therapeutic Strategy for Cervical Cancer","authors":"Md. Habib Ullah Masum,&nbsp;Rehana Parvin,&nbsp;Homaira Pervin Heema,&nbsp;Aklima Akter,&nbsp;Jannatul Ferdous","doi":"10.1002/cnr2.70434","DOIUrl":"10.1002/cnr2.70434","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>With recurrent high-risk human papillomavirus (HPV) infections, especially HPV16 and HPV18, cervical cancer is the fourth most common disease among women. The functional alterations of the E6 and E7 proteins are essential to the oncogenic process of high-risk HPVs and cervical cancer development.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>The objective of this research is to design highly targeted and efficient small interfering RNAs (siRNAs) that target both HPV16 and HPV18, employing cutting-edge computational approaches to enhance therapeutic potential through a systematic bioinformatics-driven approach.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods and Results</h3>\u0000 \u0000 <p>This study utilized the i-Score Designer to identify and evaluate four potential small interfering RNAs (siRNAs) (E6_69, E6_451, E7_66, and E7_193) based on various algorithm criteria, including Ui-Tei, Amarzguioui, i-Score, and Reynolds scores. Consequently, a docking analysis was conducted to elucidate the intermolecular interactions between the RNA-induced silencing complex (RISC) proteins and the designed siRNAs. All siRNAs passed the recommended cutoff values, indicating a strong potential for gene silencing. Thermodynamic and structural analyses revealed that the designed siRNAs had favrable melting temperatures and free energies, suggesting adequate stability for effective gene silencing. Further, docking analysis demonstrated significant binding affinities and interaction profiles with the major RISC proteins (Dicer, Ago2, TRBP). The E6_69 and E7_193 significantly showed strong binding and intermolecular interactions, especially with Ago2, highlighting the potential for HPV gene silencing.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The study revealed the potential of the designed siRNAs in silencing the E6 and E7 genes and their therapeutic applications against HPV. Future research should focus on validating these findings across various experiments, both in vivo and in vitro, and exploring alternative delivery approaches to enhance therapeutic efficacy.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 12","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12703009/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145755447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A New Radiotranscriptomic Approach to Analyze Combined Sets of T3b Stage-Specific Genes and Radiomic Features in Prostate Cancer","authors":"Qian Yang,&nbsp;Peng Tang,&nbsp;Jiao Mo,&nbsp;Qiuyang Li,&nbsp;Jiahui Huang,&nbsp;Xiaoyu Han,&nbsp;Hao Xu,&nbsp;Xi Liu,&nbsp;Jie Tang","doi":"10.1002/cnr2.70391","DOIUrl":"10.1002/cnr2.70391","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Current clinical staging of prostate cancer (PCa) using the tumor-node-metastasis (TNM) system and serum biomarkers remains limited in distinguishing locally advanced (T3b) PCa from organ-confined (T2c) disease.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>Building on our previous biomarker discovery in differentiating PCa from that of benign prostatic hyperplasia, this study pioneers a radiotranscriptomic model to distinguish T3b stage PCa from T2c stage PCa by integrating contrast-enhanced ultrasound (CEUS) radiomics with stage-specific transcriptomic signatures, addressing a critical knowledge gap in precision staging.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods and Results</h3>\u0000 \u0000 <p>This prospective study was approved by the review board of Chinese PLA General Hospital (S2021-565-01), and all participants provided written informed consent. Transrectal B-mode ultrasound images and contrast-enhanced ultrasound images on two imaging planes were prospectively analyzed in 48 patients with biopsy-confirmed PCa (35 patients with stage T2c and 13 with stage T3b). Textural features were evaluated using microvascular ultrasonography and contrast-enhanced ultrasound. Radiomic data were then retrieved from all modes. An across-the-board investigation of mRNA and miRNA expressions was also performed in the two PCa stages. Six biomarkers (frizzled 4, ribosomal protein S7, ribosomal protein L29, miR-374c, miR-9, and miR-6510) were identified to differentiate T3b stage from T2c stage. The area under the curve (AUC) values of the combined set (AUC = 0.887, 0.956, and 0.996 for random forest, naïve Bayes, and support vector machine, respectively) and radiomic features alone (AUC = 0.921, 0.957, and 0.998, respectively) were found to be more accurate than those of the transcriptomic data alone (AUC = 0.583, 0.716, and 0.898, respectively) or clinical features alone (AUC = 0.585, 0.675, and 0.953, respectively). The PCa gene regulatory network comprised of four miRNAs (miR-148, miR-141, miR-342, and miR-210) may contribute to accelerating tumor progression.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>We established the new radiotranscriptomic signatures specifically optimized for differentiating T3b stage from T2c stage by decoding stage-specific imaging-genomic crosstalk. This new approach may overcome TNM staging limitations.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 12","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70391","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145740814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Efficacy of Radiofrequency Ablation in Treating Nonmetastatic Medullary Thyroid Carcinoma: A Case Study","authors":"Hojat Ebrahiminik,&nbsp;Hossein Chegeni,&nbsp;Haleh Chehrehgosha","doi":"10.1002/cnr2.70419","DOIUrl":"10.1002/cnr2.70419","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Radiofrequency ablation (RFA) can be an alternative management method for patients who are not candidates for surgery or who refuse it. There are limited data concerning the role of RFA in patients with medullary thyroid carcinoma (MTC). This case is presented to discuss the efficacy of RFA in the management of nonmetastatic MTC.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Case</h3>\u0000 \u0000 <p>In this report, we present the case of an 83-year-old male with MTC who refused thyroidectomy. RFA was performed and he was followed for 1 year. In this case, RFA resulted in significant reductions in tumor size and calcitonin levels without any significant complications.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This research indicates that Radiofrequency Ablation (RFA) can yield acceptable results in the management of Medullary Thyroid Cancer (MTC). However, ongoing investigation remains crucial to clarify long-term outcomes and to compare RFA's efficacy against conventional management methods.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 12","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12690977/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145713424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acute Myeloid Leukemia Secondary to Radiation Therapy for Rectal Cancer: A Case Report","authors":"Ahmad Alkhaledi,&nbsp;Laila Alhaj Hussaen,&nbsp;Linda Kahla,&nbsp;Baraa Sammoud,&nbsp;Suha Giselle Ghanem","doi":"10.1002/cnr2.70379","DOIUrl":"10.1002/cnr2.70379","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Therapy-related AML (t-AML) is a subtype of acute myeloid leukemia (AML) that arises in the bone marrow and primarily affects white blood cells. It is associated with prior exposure to cytotoxic agents, including chemotherapy and radiotherapy. The risk of the disease increases with age and treatment intensity. Although t-AML represents 25%–30% of all AML cases, its occurrence following radiotherapy is relatively rare. Diagnosis is confirmed via bone marrow biopsy, with differential diagnoses including other leukemias, lymphomas, and myelodysplastic syndromes. Prognosis is generally poor. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the most effective curative option, though elderly patients often have limited eligibility due to comorbidities and poor performance status.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Case</h3>\u0000 \u0000 <p>Five years after treatment for stage IIA rectal cancer, including radiotherapy, chemotherapy, and surgery, a 77-year-old male smoker presented with fatigue, weight loss, progressive dyspnea, headache, dizziness, blurred vision, and melena. Physical examination revealed pallor, purpura, skin crusts, and pustules. Laboratory findings showed anemia, thrombocytopenia, and circulating blasts. Bone marrow biopsy confirmed lymphoid infiltration. He was diagnosed with therapy-related AML (t-AML). Despite receiving three cycles of Azacitidine, he died of septic shock 7 months later.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This case highlights the rare development of therapy-related acute myeloid leukemia in a colorectal cancer survivor following combined pelvic radiation and capecitabine plus oxaliplatin (CAPOX) chemotherapy, underscoring the importance of long-term hematologic surveillance in such patients.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 12","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12687298/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145707286","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}